ArticleFrontiers in oncology2026
Host TLR4 activation by tenascin-C is associated with MMP14-dependent glioma invasion.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most aggressive primary brain tumor in adults and is characterized by diffuse invasion and profound remodeling of the tumor microenvironment. Tumor-associated microglia and macrophages represent the largest non-malignant population in glioblastoma and promote invasive growth through context-dependent inflammatory and matrix-remodeling programs, yet the endogenous microenvironmental cues that drive their pro-invasive activation remain incompletely defined. Tenascin-C (TNC) is an extracellular matrix glycoprotein abundantly expressed in glioblastoma and a reported endogenous ligand of Toll-like receptor 4 (TLR4). Here, we investigated whether tumor-derived TNC engages TLR4 signaling in host myeloid cells, consistent with a role to promote glioma invasion through induction of matrix metalloproteinases. To this end, we combined analyses of freshly resected human glioblastoma specimens, public bulk sequencing and CISH datasets, ex vivo GL261-organotypic brain slice cultures from wild-type and TLR4-deficient mice, and primary murine microglia cultures. TLR4 expression in human glioblastoma was enriched in CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.